Alessandra Boletta Selected Research

polycystic kidney disease 1 protein

11/2018	Metabolism and mitochondria in polycystic kidney disease research and therapy.
4/2016	Phosphoinositide 3-Kinase-C2α Regulates Polycystin-2 Ciliary Entry and Protects against Kidney Cyst Formation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandra Boletta Research Topics

Disease

19	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2022 - 01/2006
10	Polycystic Kidney Diseases (Polycystic Kidney Disease) 11/2018 - 10/2009
9	Cysts 01/2020 - 01/2006
3	Neoplasms (Cancer) 01/2022 - 11/2020
2	Renal Cell Carcinoma (Grawitz Tumor) 11/2020 - 01/2018
2	Disease Progression 11/2019 - 08/2017
2	Cystic Kidney Diseases (Cystic Kidney Disease) 04/2016 - 12/2012
1	Lymphoma (Lymphomas) 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Erdheim-Chester Disease 10/2021
1	Infections 01/2021
1	Inflammation (Inflammations) 01/2021
1	Neoplasm Metastasis (Metastasis) 11/2020
1	Body Weight (Weight, Body) 01/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2020
1	Kidney Neoplasms (Kidney Cancer) 01/2019
1	Cystadenoma 01/2019
1	Papillary Carcinoma 01/2019
1	Carcinogenesis 01/2018
1	Ischemia 04/2016
1	Tuberous Sclerosis (Bourneville's Disease) 03/2016
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2016
1	Hydrocephalus (Hydrocephaly) 08/2015
1	Retinal Degeneration 11/2014
1	Ciliopathies 11/2014
1	Hypertension (High Blood Pressure) 07/2010
1	Vascular Remodeling 07/2010
1	Fibrosis (Cirrhosis) 07/2010
1	Wounds and Injuries (Trauma) 10/2007

Drug/Important Bio-Agent (IBA)

11	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2006
5	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 04/2013
3	EnzymesIBA 01/2022 - 04/2016
3	Mechanistic Target of Rapamycin Complex 1IBA 01/2020 - 01/2018
3	Sirolimus (Rapamycin)FDA Link 04/2017 - 10/2009
2	CytokinesIBA 10/2021 - 01/2021
2	ActomyosinIBA 01/2021 - 11/2019
2	FumaratesIBA 01/2019 - 01/2018
2	polycystic kidney disease 1 proteinIBA 11/2018 - 04/2016
2	Deoxyglucose (2 Deoxy D glucose)IBA 08/2017 - 01/2016
2	Phosphotransferases (Kinase)IBA 04/2017 - 10/2009
2	beta CateninIBA 12/2012 - 10/2007
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022
1	venetoclaxIBA 01/2022
1	IACS-010759IBA 01/2022
1	S63845IBA 01/2022
1	Histones (Histone)IBA 01/2021
1	AntibodiesIBA 01/2021
1	VaccinesIBA 01/2021
1	3- (2,4- dichloro- 5- methoxyphenyl)- 2- sulfanyl- 4(3H)- quinazolinoneIBA 01/2020
1	fasudil (AT 877)IBA 11/2019
1	Tricarboxylic AcidsIBA 01/2019
1	Fumarate Hydratase (Fumarase)IBA 01/2019
1	TRPP Cation ChannelsIBA 11/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	RoscovitineIBA 01/2018
1	Casein Kinases (Casein Kinase)IBA 01/2018
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2018
1	N(6)- (3- iodobenzyl)- 5'- N- methylcarboxamidoadenosineIBA 04/2017
1	Ion Channels (Ion Channel)IBA 01/2017
1	Phosphatidylinositols (Phosphatidylinositol)IBA 04/2016
1	trans-sodium crocetinate (crocetin)IBA 03/2016
1	Retinaldehyde (Retinal)IBA 11/2014
1	Rhodopsin (Visual Purple)IBA 11/2014
1	Biological ProductsIBA 02/2014
1	MTOR InhibitorsIBA 07/2010
1	Mechanistic Target of Rapamycin Complex 2IBA 07/2010
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2010
1	TOR Serine-Threonine KinasesIBA 10/2009
1	Cadherins (E-Cadherin)IBA 10/2007
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2006

Therapy/Procedure

8	Therapeutics 01/2022 - 04/2013